Department of Pathology and Laboratory Medicine.
Lineberger Comprehensive Cancer Center.
Blood. 2022 Mar 3;139(9):1374-1388. doi: 10.1182/blood.2021012537.
Genetic variants within the fibrinogen Aα chain encoding the αC-region commonly result in hypodysfibrinogenemia in patients. However, the (patho)physiological consequences and underlying mechanisms of such mutations remain undefined. Here, we generated Fga270 mice carrying a premature termination codon within the Fga gene at residue 271. The Fga270 mutation was compatible with Mendelian inheritance for offspring of heterozygous crosses. Adult Fga270/270 mice were hypofibrinogenemic with ∼10% plasma fibrinogen levels relative to FgaWT/WT mice, linked to 90% reduction in hepatic Fga messenger RNA (mRNA) because of nonsense-mediated decay of the mutant mRNA. Fga270/270 mice had preserved hemostatic potential in vitro and in vivo in models of tail bleeding and laser-induced saphenous vein injury, whereas Fga-/- mice had continuous bleeding. Platelets from FgaWT/WT and Fga270/270 mice displayed comparable initial aggregation following adenosine 5'-diphosphate stimulation, but Fga270/270 platelets quickly disaggregated. Despite ∼10% plasma fibrinogen, the fibrinogen level in Fga270/270 platelets was ∼30% of FgaWT/WT platelets with a compensatory increase in fibronectin. Notably, Fga270/270 mice showed complete protection from thrombosis in the inferior vena cava stasis model. In a model of Staphylococcus aureus peritonitis, Fga270/270 mice supported local, fibrinogen-mediated bacterial clearance and host survival comparable to FgaWT/WT, unlike Fga-/- mice. Decreasing the normal fibrinogen levels to ∼10% with small interfering RNA in mice also provided significant protection from venous thrombosis without compromising hemostatic potential and antimicrobial function. These findings both reveal novel molecular mechanisms underpinning fibrinogen αC-region truncation mutations and highlight the concept that selective fibrinogen reduction may be efficacious for limiting thrombosis while preserving hemostatic and immune protective functions.
纤维蛋白原 Aα 链编码 αC 区的遗传变异通常导致患者出现低纤维蛋白原血症。然而,这种突变的(病理)生理后果和潜在机制仍未确定。在这里,我们生成了 Fga270 小鼠,其 Fga 基因在残基 271 处携带一个过早终止密码子。Fga270 突变与杂合杂交后代的孟德尔遗传相容。成年 Fga270/270 小鼠的纤维蛋白原水平约为 FgaWT/WT 小鼠的 10%,这与由于突变 mRNA 的无意义介导的衰变导致肝 Fga 信使 RNA (mRNA) 减少 90%有关。Fga270/270 小鼠在尾出血和激光诱导的隐静脉损伤模型中的体外和体内止血潜能得到保留,而 Fga-/- 小鼠则持续出血。FgaWT/WT 和 Fga270/270 小鼠的血小板在腺苷 5'-二磷酸刺激后显示出相当的初始聚集,但 Fga270/270 血小板很快发生解聚。尽管血浆纤维蛋白原水平约为 10%,但 Fga270/270 血小板中的纤维蛋白原水平约为 FgaWT/WT 血小板的 30%,纤维连接蛋白代偿性增加。值得注意的是,Fga270/270 小鼠在腔静脉淤滞模型中完全免受血栓形成的影响。在金黄色葡萄球菌腹膜炎模型中,Fga270/270 小鼠支持局部纤维蛋白原介导的细菌清除和宿主存活,与 FgaWT/WT 相似,而与 Fga-/- 小鼠不同。用小干扰 RNA 将正常纤维蛋白原水平降低至约 10%也能显著预防静脉血栓形成,而不会影响止血潜能和抗微生物功能。这些发现揭示了纤维蛋白原 αC 区截断突变的新分子机制,并强调了选择性降低纤维蛋白原可能有效限制血栓形成,同时保留止血和免疫保护功能的概念。